Successful treatment of active ankylosing spondylitis with the anti- tumor necrosis factor α monoclonal antibody infliximab

Arthritis and Rheumatism

Volumn 43, Issue 6, 2000, Pages 1346-1352

  Brandt, Jan ^a   Haibel, Hildrun ^a   Cornely, Daniel ^a   Golder, Werner ^a   Gonzalez, José ^a   Reddig, Jaqueline ^b   Thriene, Wolfgang ^b   Sieper, Joachim ^a   Braun, Jürgen ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Essex Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 6;

ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; XANTHOMA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MIDDLE AGED; PALLIATIVE CARE; PILOT PROJECTS; SPINE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034094123     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E     Document Type: Article

References (35)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Sieper J, Braun J. Pathogenesis of spondylarthropathies: persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995; 38:1547-54.
3. Braun J, Sieper J. The sacroiliac joint in the spondylarthropathies. Curr Opin Rheumatol 1996;7:275-83.
4. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24: 697-735.
5. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. J Rheumatol 2000;27:613-22.
6. Braun J, Bollow M, Seyrekbasan SF, Häberle H-J, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-64.
7. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38: 499-505.
8. Braun J, Tuszewski M, Ehlers S, Häberle J, Bollow M, Eggen U, et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol 1997;24:1101-5.
9. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
10. Mielants H, Veys EM, Cuvelier C, de Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64.
11. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarland JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
12. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
13. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
14. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
15. Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath AS Disease Activity Index. J Rheumatol 1994;21:2286-91.
16. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-α, IL-1 beta and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
17. Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
18. Bollow M, Brandt J, Häberle HJ, Schmitz S, Sieper J, Hamm B, et al. Use of magnetic resonance imaging to detect spinal inflammation in spondyloarthropathy patients [abstract]. Arthritis Rheum 1998;41 Suppl 9:S358.
19. Van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden, on behalf of the Assessments in Ankylosing Spondylitis Working Group. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997;24:2225-9.
20. Calin A, Nakache J-P, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38:878-82.
21. Calin A, Garrett S, Whitelock HC, Kennedy LG, O'Hea J, Mallorie PA, et al. A new approach to defining functional ability in ankylosing spondylitis: the Bath AS Functional Index. J Rheumatol 1994;21:2286-91.
22. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett S, Calin A. Defining spinal mobility in ankylosing spondylitis: the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
23. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
24. Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, et al. Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol 1999;26:997-1002.
25. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24: 737-51.
26. Antoni C, Dechant C, Lorenz H, Olgivie A, Kalden-Nemeth D, Kalden J, et al. Successful treatment of severe psoriatic arthritis with infliximab [abstract]. Arthritis Rheum 1999;42 Suppl 9:S371.
27. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999;42:580-1.
28. Calin A, Nakache J-P, Gueguen A, Zeidler H, Mielant H, Dougados M. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. J Rheumatol 1999; 26:975-9.
29. Ward MM. Health-related quality of life in ankylosis spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
30. Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 1996;23:487-90.
31. Höhler T, Schaper T, Schneider PM, Meyer zum Büschenfelde K-H, Märker-Hermann E. Association of different tumor necrosis factor α promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998;41:1489-92.
32. Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor α, hut no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999;42:2039-44.
33. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFα and IFNγ in ankylosing spondylitis is related to HLA B27 and influenced by TNF-308 gene polymorphism. Submitted for publication.
34. Repo H, Lauhio A, Jäättelä M, Saikkü P, Leirisalo-Repo M. Peripheral blood monocytes from patients with reactive arthritis show normal production of tumour necrosis factor-alpha. Clin Exp Immunol 1991;83:516-7.
35. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RAW, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:2166-73.